Trevi Therapeutics, Inc. (NASDAQ:TRVI) Insider Sells $548,862.75 in Stock

Trevi Therapeutics, Inc. (NASDAQ:TRVI) insider Farrell Simon sold 81,313 shares of the stock in a transaction on Monday, March 10th. The stock was sold at an average price of $6.75, for a total value of $548,862.75. Following the completion of the transaction, the insider now owns 76,900 shares of the company’s stock, valued at $519,075. The trade was a 51.39 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Trevi Therapeutics Trading Down 0.2 %

NASDAQ:TRVI opened at $6.29 on Friday. Trevi Therapeutics, Inc. has a 12-month low of $2.30 and a 12-month high of $7.39. The firm has a market cap of $483.49 million, a price-to-earnings ratio of -14.30 and a beta of 0.90. The company’s 50-day moving average is $4.30 and its two-hundred day moving average is $3.60.

Hedge Funds Weigh In On Trevi Therapeutics

A number of institutional investors have recently modified their holdings of the company. Frazier Life Sciences Management L.P. boosted its position in Trevi Therapeutics by 44.5% during the fourth quarter. Frazier Life Sciences Management L.P. now owns 10,664,774 shares of the company’s stock worth $43,939,000 after acquiring an additional 3,283,684 shares during the last quarter. Point72 Asset Management L.P. acquired a new stake in shares of Trevi Therapeutics during the fourth quarter worth $17,099,000. Vivo Capital LLC boosted its holdings in shares of Trevi Therapeutics by 116.3% during the fourth quarter. Vivo Capital LLC now owns 3,487,903 shares of the company’s stock worth $14,370,000 after purchasing an additional 1,875,000 shares during the last quarter. Woodline Partners LP grew its position in shares of Trevi Therapeutics by 429.9% in the fourth quarter. Woodline Partners LP now owns 3,212,597 shares of the company’s stock valued at $13,236,000 after purchasing an additional 2,606,370 shares during the period. Finally, MPM Bioimpact LLC increased its stake in Trevi Therapeutics by 101.2% in the fourth quarter. MPM Bioimpact LLC now owns 3,094,896 shares of the company’s stock valued at $12,751,000 after purchasing an additional 1,556,379 shares during the last quarter. Institutional investors and hedge funds own 95.76% of the company’s stock.

Wall Street Analyst Weigh In

TRVI has been the topic of a number of recent analyst reports. Raymond James raised shares of Trevi Therapeutics from an “outperform” rating to a “strong-buy” rating and upped their price target for the stock from $9.00 to $29.00 in a research note on Monday. Needham & Company LLC upped their target price on shares of Trevi Therapeutics from $8.00 to $25.00 and gave the stock a “buy” rating in a research report on Monday. HC Wainwright lifted their price target on shares of Trevi Therapeutics from $7.50 to $12.50 and gave the company a “buy” rating in a research report on Monday. Oppenheimer raised their price objective on Trevi Therapeutics from $12.00 to $20.00 and gave the company an “outperform” rating in a research note on Tuesday. Finally, D. Boral Capital reiterated a “buy” rating and issued a $21.00 price objective on shares of Trevi Therapeutics in a research report on Friday, March 7th. Seven research analysts have rated the stock with a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $15.94.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.